Akebia partners with Otsuka on anemia drug

The Japanese co Otsuka will pay $125 million upfront, with another $140 million in committed funds tied to global development of vadadustat. 

By Suzanne Elvidge • Dec. 21, 2016

Allergan picks up regenerative med company for $2.9B

Since Allergan sold its generics business to Teva, CEO Brent Saunders has stayed true to his "stepping stone" dealmaking strategy. 

By Ned Pagliarulo • Dec. 20, 2016

Conatus soars on Novartis deal

The Swiss pharma put up $50 million to gain access to Conatus' experimental NASH drug, joining a growing list of biopharmas investing in the space.

By Ned Pagliarulo • Dec. 20, 2016

Bristol continues immuno-oncology push in deal with PsiOxus

The deal could be worth more than $930 million, and gives Bristol-Myers exclusive rights to a pre-clinical oncolytic virus therapy.

By Jacob Bell • Dec. 20, 2016

AstraZeneca uses Ionis to make sense from antisense

The $28 million milestone payment reflects progress in AstraZeneca's cancer pipeline.

By Suzanne Elvidge • Dec. 19, 2016

Prescribed Reading: Bad behavior abounds in biopharma

Charges have come down in a generics price-fixing investigation, while Ophthotech reports deep staff cutbacks and the FDA cautions on misleading advertising.

By Lisa LaMotta • Dec. 16, 2016

Celgene, Evotec team up on neurological treatments

The big biotech will pay the German drug discovery company $45 million upfront as part of the partnership.

By Jacob Bell • Dec. 16, 2016

Lonza swallows Capsugel in deal worth $5.5B

The deal caps off what has been a year of expansion for the Swiss drug manufacturer's pharmaceutical platform.

By Jacob Bell • Dec. 15, 2016

Grünenthal picks up rights to pain patch from Astellas

The German biopharma now holds the rights to market a capsaicin-based treatment for neurological pain in Europe, Africa and the Middle East.

By Jacob Bell • Dec. 13, 2016

Lilly, Express Scripts team up on insulin discount program

The pharma is playing nice with the PBM to help solidify its place in the competitive diabetes market. 

By Lisa LaMotta • Dec. 13, 2016

Almirall inks deal for Nuevolution's derm program

Spanish and Danish companies will collaborate on new class of NSAIDs.

By Suzanne Elvidge • Dec. 13, 2016

Purdue lands rights to psoriasis drug in diversification deal

Under scrutiny for its portfolio of pain drugs, Purdue is trying its hand in other areas of drug development. 

By Ned Pagliarulo • Dec. 12, 2016

Lilly and AZ hook up again for Alzheimer's

Lilly sticks with the amyloid approach in Alzheimer's even amid the recent high-profile failure of solanezumab.

By Suzanne Elvidge • Dec. 12, 2016

After rough 2016, markets to open for emerging biotech

It was a slow year for biotechs, with dealmaking and IPOs taking a back seat. But innovation and amazing science are at a peak, suggesting M&A will pick up. 

By Lisa LaMotta • Dec. 12, 2016

Endo chops sales force after ditching pain drug

The Irish biopharma plans to pump the resources saved from the decision into its branded drug portfolio.

By Jacob Bell • Dec. 8, 2016

Acticor taps Merck's MilliporeSigma for manufacturing services

The German company's US business ties up a manufacturing deal with a French biotech.

By Suzanne Elvidge • Dec. 8, 2016

Sanofi taps JHL for access to biosimilars in China

The French pharma hopes to gain access to the growing pharmaceutical market in China through the deal. 

By Suzanne Elvidge • Dec. 7, 2016

Spark teams up with Selecta on gene therapies

The gene therapy biotech will use Selecta's technology platform to bolster the efficacy of its hemophilia therapies. 

By Lisa LaMotta • Dec. 5, 2016

Acetylon forms Regenacy ahead of Celgene takeover

Boston biotech Acetylon revealed it was being acquired by Celgene and rolled out a new business to continue production of gene expression drugs. 

By Jacob Bell • Dec. 5, 2016

Prescribed Reading: Spotlight on CAR-T, Cures

AstraZeneca inks small deal that will fit into its new focus; the upcoming ASH meeting will highlight the progress in CAR-T; and the Cures Act gets support from the industry. 

By Lisa LaMotta • Dec. 2, 2016

Roche brings Kapa into partnership with German Merck

The Swiss biopharma has expanded two distribution deals this week, one for its own enzyme products and one for another drugmaker's diabetes technology.

By Jacob Bell • Dec. 2, 2016

Little meets large: Bicycle inks deal with AstraZeneca

The small UK biotech believes its peptide technology combines the targeting specificity of antibodies with the dosing flexibility of small molecules. 

By Suzanne Elvidge • Dec. 2, 2016

Sangamo to transfer two gene therapies to Biogen spin-off

Adding the hemoglobinopathy programs, which Sangamo had partnered with Biogen on, will bolster the fledgling Bioverativ's pipeline in rare blood disorders. 

By Judy Packer-Tursman • Dec. 1, 2016

Patheon snaps up SC manufacturing site from Roche

The Swiss pharma has been trimming its small molecule manufacturing network, tagging four plants worldwide for sale. 

By Judy Packer-Tursman • Nov. 30, 2016

Oxford BioMedica and Orchard ink gene therapy deal

Strategic alliance combines gene and cell therapy approaches for rare immune diseases.

By Suzanne Elvidge • Nov. 30, 2016